ROTHBLATT MARTINE A sold $5.1M of UTHR

United Therapeutics (UTHR) shares are under scrutiny after the FDA accepted its NDA for ralinepag, a treatment for pulmonary arterial hypertension, with a target action date set for June 24, 2027. The company's stock has seen a 1-year return of 67.69% and a 5-year return of 141.31%, but has dipped 9.15% in the past 90 days. Analysts suggest potential undervaluation, with a narrative fair value of $665.23 compared to the recent close of $518.53, citing its pipeline and long-term growth prospects.

The FDA accepted United Therapeutics' NDA for ralinepag, a PAH treatment, with a PDUFA target date of June 24, 2027. The application is based on Phase III trial results showing a 55% reduction in clinical worsening events. If approved, ralinepag would be the first once-daily oral prostacyclin IP receptor agonist for PAH. The company also plans to develop a dry powder inhalation formulation with MannKind.

United Therapeutics (NASDAQ: UTHR) reported Q2 2026 revenues of $783.3 million, down 2% year over year, and net income per diluted share of $7.27 versus $6.41. Tyvaso DPI sales were $326.6 million, while nebulized Tyvaso fell 18% to $126.0 million. Management discussed a path to a $4 billion 2027 revenue run rate amid competitive pressure and upcoming IPF and PAH launches.

United Therapeutics Corporation reported Q2 2026 sales of $783.3M versus $798.6M a year earlier. Net income was $333.0M versus $309.5M. Basic EPS from continuing ops was $7.82 versus $6.86, and diluted EPS was $7.27 versus $6.41. For six months, sales were $1,564.8M versus $1,593.0M; net income $607.9M versus $631.7M.

United Therapeutics (NASDAQ: UTHR) reported Q2 CY2026 revenue of $783.3 million, down 1.9% year over year but 2.3% above Wall Street estimates, according to the company. GAAP EPS was $7.27, up from $6.41 and 5.9% above consensus. Analysts expect revenue to decline 20.9% over the next 12 months.

United Therapeutics (UTHR) reported Q2 2026 earnings of $7.27 per share, above the $6.97 estimate. Revenue was $783.3 million, below the $821.8 million estimate. The article also cites insider sales totaling 1,373 trades over six months, and notes a median analyst price target of $660.